Rhubarb and reliability - A Jane Austen view of systemic lupus erythematosus

Journal of Rheumatology

Volumn 40, Issue 1, 2013, Pages 7-8

  Isenberg, David A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BIOLOGICAL MARKER; RHUBARB ANTIBODY; UNCLASSIFIED DRUG;

CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE ACTIVITY; DISEASE ASSOCIATION; EDITORIAL; HUMAN; MEDICAL SOCIETY; ONLINE SYSTEM; PATIENT ASSESSMENT; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RELIABILITY; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT PLANNING; TREATMENT RESPONSE; VALIDITY;

ATTITUDE OF HEALTH PERSONNEL; FEMALE; HEALTH CARE SURVEYS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RHEUMATOLOGY;

EID: 84871884419     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121224     Document Type: Editorial

References (11)

1. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18. (Pubitemid 19237865)
2. Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: Updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Res 2011;63 Suppl:S37-46.
3. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58. (Pubitemid 23223653)
4. Yee CS, Farewell V, Isenberg DA, Prabu A, Sokoll K, Teh LS, et al. Revised British Isles Lupus Assessment Group 2004 index: A reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum 2006;54:3300-5. (Pubitemid 44622101)
5. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
6. Chang ER, Abrahamowicz M, Ferland D, Fortin PR. Organ manifestations influence differently the responsiveness of 2 lupus disease activity measures, according to patients' or physicians' evaluations of recent lupus activity. J Rheumatol 2002;29:2350-8. (Pubitemid 35266025)
7. Gladman DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29:288-91. (Pubitemid 34118775)
8. Touma Z, Urowitz MB, Ibanez D, Gladman DD. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus 2011;20:67-70.
9. Furie R, Petri M, Zamani O, Cervera R, Walker DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30.
10. Touma Z, Gladman DD, Ibanez D, Urowitz MB. Development and initial validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50. J Rheumatol 2011;38:275-84.
11. Touma Z, Gladman DD, MacKinnon A, Carette S, Abu-Shakra M, Askanase A, et al. Development and assessment of users' satisfaction of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 (S2K RI-50) Website. J Rheumatol 2013;40:34-9.